## Abstract 6‐Chloro‐3‐((2‐(__S__)‐azetidinyl)methoxy)‐5‐((__E__)‐2‐(2‐[^18^F]fluoropyridin‐4‐yl)vinyl)pyridine ([^18^F]NIDA 52289), a very high affinity radioligand for studying nicotinic acetylcholine receptors (nAChRs) by positron‐emission tomography, was synthesized through Kryptofix 222 assist
Synthesis of 6-chloro-3-((2-(S)-azetidinyl)methoxy)-5-(2-[18F]fluoropyridin-4-yl)pyridine ([18F]NIDA 522131), a novel potential radioligand for studying extrathalamic nicotinic acetylcholine receptors by PET
✍ Scribed by Yi Zhang; Andrew G. Horti
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- French
- Weight
- 99 KB
- Volume
- 47
- Category
- Article
- ISSN
- 0022-2135
- DOI
- 10.1002/jlcr.883
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
6‐Chloro‐3‐((2‐(S)‐azetidinyl)methoxy)‐5‐(2‐[^18^F]fluoropyridin‐4‐yl)pyridine ([^18^F]NIDA 522131), a potential radioligand for studying extrathalamic nicotinic acetylcholine receptors by positron‐emission tomography, was synthesized via no‐carrier‐added nucleophilic [^18^F]fluorination of 6‐chloro‐3‐((1‐(tert‐butoxycarbonyl)‐2‐(S)‐azetidinyl)methoxy)‐5‐(2‐iodopyridin‐4‐yl)vinyl)pyridine, followed by acidic deprotection. The overall radiochemical yield of the radiosynthesis was 4–8% (non‐decay‐corrected), the specific radioactivity was in the range of 167–335 GBq/µmol (4500–9000 mCi/µmol) and the radiochemical purity was greater than 99%. Preparation of [^18^F]NIDA522131 via corresponding bromo‐derivative 2 is also described. Copyright © 2004 John Wiley & Sons, Ltd.
📜 SIMILAR VOLUMES
Nicotinic acetylcholine receptors are widely distributed throughout the human brain and are believed to play a role in several neurological and psychiatric disorders. In order to identify an effective PET radioligand for in vivo assessment of the a4b2 subtype of nicotinic receptor, we synthesized [
2-exo-(2 0 -Fluoro-3 0 -(4-fluorophenyl)-pyridin-5 0 -yl)-7-azabicyclo[2.2.1]heptane (F 2 PhEP), a novel, epibatidine-based, a4b2-selective nicotinic acetylcholine receptor antagonist of low toxicity, as well as the corresponding N-Boc-protected chloro-and bromo derivatives as precursors for labelli